[Effects of enalapril on NF-kappaB expression in mucus hypersecretion rats induced by acrolein exposure].
OBJECTIVE
To investigate the effects of enalapril on nuclear factor-kappa B (NF-kappaB) expression in a rat model of mucus hypersecretion induced by acrolein.


METHODS
The rat model of mucus hypersecretion was established by the inhalation of acrolein. Then the mucus hypersecretion rats were treated by enalapril. The AB/PAS stain was performed to measure the secretion of airway in the rats, while the mRNA and protein expression levels of NF-kappaB in the airway were detected by RT-PCR, ISH, immunohistochemistry and Western blot.


RESULTS
With the inhalation of acrolein, the airway secretion increased obviously, while the mRNA and protein expressions of NF-kappaB in lung were increased. The treatment of enalapril resulted in a significant decrease of airway secretion, as well as the downregulation of NF-kappaB in both protein and gene level.


CONCLUSIONS
Enalapril (ACE inhibitor) treatment could effectively decrease pulmonary mucus hypersecretion in acrolein-treated rats, which may be related to the downregulation of NF-kappaB expression.
Department of Respiration, the First Affiliated Hospital of Yunnan Province, Kunming Medical College, Kunming 650000, China.
Yun-hui
YH
Zhang
Sheng-lan
SL
Wang
Qi-qin
QQ
Dan
Yan
Y
Tan
Bu-lian
BL
Meng
Yun-chao
YC
Huang
D000171:Acrolein / Q000633:toxicity*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D004656:Enalapril / Q000494:pharmacology / Q000627:therapeutic use*; D004781:Environmental Exposure / Q000009:adverse effects; D008168:Lung / Q000378:metabolism; D008171:Lung Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism*; D008297:Male; D009093:Mucus / Q000378:metabolism; D016328:NF-kappa B / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley
D000806:Angiotensin-Converting Enzyme Inhibitors; D016328:NF-kappa B; D012333:RNA, Messenger; D004656:Enalapril; D000171:Acrolein